Uncovering Necroptosis in Alzheimer’s Disease: A Systematic Review of Evidence Across Experimental Models
Open Access
- 3 October 2025
- journal article
- review article
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 45 (1) , 1-20
Abstract
Alzheimer's disease (AD), one of the most challenging neurodegenerative disorders, with high prevalence worldwide, is characterized by progressive cognitive decline and accumulation of amyloid-β plaques and neurofibrillary tau tangles. Despite significant research, the limited efficacy of current treatments underscores the critical need to identify novel pathogenic mechanisms and therapeutic targets. Necroptosis, a regulated and highly inflammatory form of programmed cell death, has emerged as one of the key contributors to AD pathogenesis. This systematic review comprises 25 high-quality in vivo, in vitro, and autopsy studies, published between 2015 and 2025, extracted from PubMed, Scopus, and Science Direct databases. The keywords include "necroptosis", "RIPK1", "RIPK3", "MLKL", "pMLKL", "necroptosis inhibitors", "Alzheimer’s disease", and "neurodegeneration". The review summarizes the multiple molecular mechanisms, including TNF-α/TNFR1 signaling, TRIF-mediated RIPK3 activation, and RHIM-dependent MLKL phosphorylation, associated with necroptosis in the pathogenesis of AD. All the studies converge on necroptosis as a central pathogenic pathway linking key molecular and cellular abnormalities observed in AD. The accumulated evidence strongly supports prioritizing the development of brain-penetrant necroptosis inhibitors and clinical validation of associated biomarkers. These insights signal a significant shift in AD therapeutics, moving from symptomatic treatment to mechanistically targeted interventions that can alter disease progression.Keywords
This publication has 108 references indexed in Scilit:
- Regulation of neuroimmune processes by damage- and resolution-associated molecular patternsNeural Regeneration Research, 2020
- Apelin attenuates streptozotocin-induced learning and memory impairment by modulating necroptosis signaling pathwayInternational Immunopharmacology, 2020
- DHA attenuates Aβ-induced necroptosis through the RIPK1/RIPK3 signaling pathway in THP-1 monocytesBiomedicine & Pharmacotherapy, 2020
- EGb761 ameliorates cell necroptosis by attenuating RIP1-mediated mitochondrial dysfunction and ROS production in both in vivo and in vitro models of Alzheimer’s diseaseBrain Research, 2020
- Molecular Insights into the Mechanism of Necroptosis: The Necrosome as a Potential Therapeutic TargetCells, 2019
- Targeting RIPK1 for the treatment of human diseasesProceedings of the National Academy of Sciences, 2019
- Identification of a novel class of RIP1/RIP3 dual inhibitors that impede cell death and inflammation in mouse abdominal aortic aneurysm modelsCell Death & Disease, 2019
- Necroptosis and RIPK1-mediated neuroinflammation in CNS diseasesNature Reviews Neuroscience, 2018
- Necroptosis activation in Alzheimer's diseaseNature Neuroscience, 2017
- Nec‐1 alleviates cognitive impairment with reduction of Aβ and tau abnormalities in APP/PS1 miceEMBO Molecular Medicine, 2016